Dec 14, 2012 2:37 AM
Where are the idiots who said it topped out at 2.8 or that they were short at 2.5?
I notice they don't post anymore. I told them to cover in the 2.3's, that was their last best chance.
Why do you waste so much energy on crickets, I looked at the Insider activity, it looks promising. Even the institutional transactions look good. I see a good chance of a pop up in the near future due to the fact that this is a biofarma but not sure how near. Good luck and happy Holidays to both Longs and Shorts.
First, we all have to "thank" Pucci for screwing us all. Getting a good compensation, he has no incentives to do anything useful for the company and its shareholders.
My new 2013 year wishes:
- Get good results in Ph2 trials in mCRC, prostate, breast, mKRAS NSCLC as well in Marquee and Attention readouts - ARQL being bought out in 2H 2013 for $30+ (just over $1.7B). This is a very low price for a company with a promising drug in multiple cancer settings. But with incompetent bureaucrat, no-English speaking Pucci, it is difficult to expect much.
More LinksSummaryHistorical PricesInteractive ChartHeadlinesMarket PulseCompetitorsKey StatisticsInsider TransactionsIncome StatementBalance SheetCashflowTechnical Analysis Top Stories Greeks defy Europe with overwhelming referendum 'No' Euro, stocks hit by Greek vote; China rebounds Chinese stocks rise after Beijing unleashes emergency support Euro markets set for major jolt after Greek 'No', look to ECB for calm Oil prices tumble after Greece vote, China stock market turmoil China state media see a 'rainbow' after latest steps to stabilize slumping … 1.62+0.06(+3.85%)Jul 2 4:00 PMEDT
Dec 14, 2012 2:37 AM
Where are the idiots who said it topped out at 2.8 or that they were short at 2.5?
I notice they don't post anymore. I told them to cover in the 2.3's, that was their last best chance.
Why do you waste so much energy on crickets, I looked at the Insider activity, it looks promising. Even the institutional transactions look good. I see a good chance of a pop up in the near future due to the fact that this is a biofarma but not sure how near. Good luck and happy Holidays to both Longs and Shorts.
First, we all have to "thank" Pucci for screwing us all. Getting a good compensation, he has no incentives to do anything useful for the company and its shareholders.
My new 2013 year wishes:
- Get good results in Ph2 trials in mCRC, prostate, breast, mKRAS NSCLC as well in Marquee and Attention readouts - ARQ
L being bought out in 2H 2013 for $30+ (just over $1.7B). This is a very low price for a company with a promising drug in multiple cancer settings. But with incompetent bureaucrat, no-English speaking Pucci, it is difficult to expect much.
More LinksSummaryHistorical PricesInteractive ChartHeadlinesMarket PulseCompetitorsKey StatisticsInsider TransactionsIncome StatementBalance SheetCashflowTechnical Analysis Top Stories Greeks defy Europe with overwhelming referendum 'No' Euro, stocks hit by Greek vote; China rebounds Chinese stocks rise after Beijing unleashes emergency support Euro markets set for major jolt after Greek 'No', look to ECB for calm Oil prices tumble after Greece vote, China stock market turmoil China state media see a 'rainbow' after latest steps to stabilize slumping … 1.62+0.06(+3.85%)Jul 2 4:00 PMEDT